Peripheral CB1R as a modulator of metabolic inflammation.

Obesity is associated with chronic inflammation in insulin-sensitive tissues, including liver and adipose tissue, and causes hormonal/metabolic complications, such as insulin resistance. There is growing evidence that peripheral cannabinoid-type 1 receptor (CB1R) is a crucial participant in obesity-induced pro-inflammatory responses in insulin-target tissues, and its selective targeting could be a novel therapeutic strategy to break the link between insulin resistance and metabolic inflammation. In this review, we introduce the role of peripheral CB1R in metabolic inflammation and as a mediator of hormonal/metabolic complications that underlie metabolic syndrome, including fatty liver, insulin resistance, and dyslipidemia. We also discuss the therapeutic potential of second- and third-generation peripherally restricted CB1R antagonists for treating obesity-induced metabolic inflammation without eliciting central CB1R-mediated neurobehavioral effects, predictive of neuropsychiatric side effects, in humans. © 2020 Federation of American Societies for Experimental Biology.

Citation

Ji Hye Han, Wook Kim. Peripheral CB1R as a modulator of metabolic inflammation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2021 Apr;35(4):e21232

Mesh Tags

Substances

PMID: 33715173

search → result